Accord EMENA Chief Says Industry Is Pushing Back On Pressures
Inflation, Pricing Constraints And Shortages Follow Fallout From Pandemic
Executive Summary
Amid continuing cost inflation, downwards pressure on prices, industry shortages and other supply-chain disruptions, Paul Tredwell – Accord’s executive vice-president for the Europe, Middle East and North Africa region – talks about how the off-patent industry is seeking to improve its operating environment.
You may also be interested in...
Accord Sees Benefits From Unique Portfolio
With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.
Industry Speaks Out On Global Antibiotics Shortages
Responding to shortages of antibiotics seen around the world, the IGBA has insisted that the generics industry is working to address spikes in demand and has set out a series of recommendations to mitigate the situation. Meanwhile, US association the AAM has countered suggestions that supply issues are due to a “broken generic drug market.”
Accord Unveils New Ventures After A Year Of Change
A year after taking up the lead for Accord in the EMENA region, Paul Tredwell talks to Generics Bulletin in detail about the changes that he has already overseen in the role, as well as unveiling a number of new business initiatives, acquisitions and appointments that form part of his long-term growth strategy.